Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 17Completed 6Not yet recruiting 5Active not recruiting 4Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 12Prostatic Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 5Breast Neoplasms 5Recurrence 4Multiple Myeloma 4Lymphoma, B-Cell 4Lymphoma 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Cancer Pain 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Kidney Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all
NCT06769555 2026-04-29

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡